Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Demand for Biological Data Explosion Drives

Boston, April 01, 2026 (GLOBE NEWSWIRE) — The global market for cloud computing in cell biology, genomics and drug development is estimated to grow from $6.2 billion in 2024 to $15.6 billion in 2030, showing a compound annual growth rate (CAGR) of 16.7% according to a report new BCC,

report, Cloud Computing in Cell Biology, Genomics and Drug Development: Global Marketsprovides a detailed analysis of the platforms, services and processes driving cloud adoption across the life sciences research and drug development value chain.

Key Findings

• The market will reach $15.6 billion by 2030which is growing at a strong 16.7% CAGR – one of the fastest growth rates in the life sciences – driven by a strong increase in the production of biological data and the demand for scalable computational resources.
• North America leads with a market share of 44.7%.which reflects the performance of the pharmaceutical R&D ecosystem, genomics research centers and network investment.
• The explosion of biological data is the driving force behind the growth. Next-generation sequencing, single-cell omics, spatial transcriptomics and high-resolution imaging are generating datasets that far exceed the capabilities of structural genomics.
• The combination of AI and advanced analytics is accelerating cloud adoptionas machine learning work continues in drug target identification, molecular simulation and clinical trial optimization require cloud computing resources and specialized GPU/TPU resources.
• Cloud-native bioinformatics SaaS platforms are changing the competitive landscapeenabling small biotech firms and academic laboratories to access enterprise-class computing capabilities without significant investment in IT infrastructure.
• Key players include cloud hyperscalers and life sciences specialistsincluding Alphabet / Google, Amazon Web Services, Benchling, Cisco, Cognizant, DNAnexus, IBM, Microsoft, Oracle, Rescale, Salesforce and SAP.

Market Drivers

The market is being driven by many converging forces. The huge amount of biological data being generated – from genomics, proteomics, metabolomics and imaging – is growing exponentially and requires serious cloud resources. Organized forms of R&D, accelerated by this pandemic, have made cloud collaboration platforms essential rather than optional. The integration of AI/ML into drug discovery pipelines requires computational elasticity that only cloud platforms can provide. And regulatory frameworks are increasingly embracing cloud-based data management in regulated life sciences environments.

Investment Ideas

Cloud computing applications for life sciences represent a structural growth opportunity as the industry transitions from on-premises to cloud-native workflows. The 16.7% CAGR shows the first phase of cloud adoption in many life sciences organizations and the rapid data production processes that make cloud migration even more necessary. Companies that offer technology-specific cloud platforms — especially those that combine AI capabilities with regulatory control — are positioned for sustainable growth.

About the Report

Cloud Computing in Cell Biology, Genomics and Drug Development: Global Markets provides comprehensive market size, segmentation by service model, application area and geography, competitive intelligence, technology analysis and strategic forecast to 2030.

For more information or to download the report, visit https://www.bccresearch.com/market-research/biotechnology/cloud-computing-for-cell-biology-genomics-market-report.html

About BCC Research

BCC Research provides objective, unbiased measurement and analysis of market opportunities through detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and evolving market opportunities, and provide valuable information and innovative decision support tools to help inform the strategic decision-making process.